SUS may involve a new treatment for kidney disease

The National Commission for the Integration of Technologies into the Unified Health System (Conitec) initiative comes at a time when 16.8 million Brazilians are living with diabetes, one of the main causes of chronic kidney disease (CKD) in Brazil. The number could reach 23.2 million patients by 2045 and up to 40% of them may develop some degree of renal impairment throughout their lives. Without proper treatment, diabetes can lead to kidney failure, requiring dialysis or a kidney transplant, which increases the risk of serious complications.

Experts also warn that Brazil is at a critical moment in public renal health, with more than 150,000 people dependent on dialysis, while SUSrel-affiliated clinics are leading to financial difficulties and the risk of closure – a situation that has been called a “humanitarian dialysis crisis” by the Brazilian Society of Nephrology. “To reduce the overburdened public health system,” says José A. Moranito, President of the Brazilian Society of Nephrology.

Recent studies with verenone show a possible 23% reduction in the risk of renal outcomes, a 20% reduction in the risk of progression to dialysis and/or kidney transplantation, and even a 30% reduction in albuminuria when associated with standard day 14 therapy (a marker of renal and cardiovascular risk).

“The public consultation represents an important opportunity for health professionals, patients and citizens in general to contribute to this debate. Community participation strengthens the evaluation process and ensures more transparency in decisions regarding the integration of technologies into the unified health system,” adds Dr. Moranito.